Both Atomoxetine and Stimulants Improve Quality
of Life in an ADHD Population Treated in a Community
Published online: 8 March 2008
Ó Springer Science+Business Media, LLC 2008
To evaluate change in quality of life in a community clinic ADHD population
treated with atomoxetine or stimulants. No direct comparisons between atomoxetine and
stimulants to improve quality of life in ADHD are available.
A prospective, nonrandomized comparison between ADHD patients treated
with atomoxetine or stimulants in one clinic. Structured diagnostic assessment tools and a
speciﬁc quality of life measure were used.
84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5 and
18, were treated for approximately 8 months. At end point, there were no signiﬁcant
differences in improvements of quality of life between the two groups. Age, participation
in psychotherapy, and parental disability were not correlated with quality of life changes.
Patients with lower baseline scores improved most.
Both atomoxetine and stimulants led to a modest increase in quality of life
in this community clinic ADHD population.
Keywords ADHD Á Quality of life Á Atomoxetine Á Stimulants
It has long been recognized that quality-of-life is signiﬁcantly impaired in patients
suffering from ADHD [1, 2]. Pharmacological treatment of ADHD has shown to improve
quality of life. Most investigations of this important variable, however, were done as part
of controlled research studies, and have focused on treatment with atomoxetine . While
some data on quality of life in pediatric ADHD patients treated with stimulants have been
presented at national meetings, no published reports are available . Also, no direct
L. Bastiaens (&)
Family Services of Western Pennsylvania, University of Pittsburgh, 33 Sunnyhill Drive,
Pittsburgh, PA 15228, USA
Psychiatr Q (2008) 79:133–137